广西梧州中恒集团股份有限公司第十届监事会第十五次会议决议公告

Group 1 - The company held the 15th meeting of the 10th Supervisory Board on June 13, 2025, with all three supervisors participating in the voting, which complied with relevant regulations [2][4] - The Supervisory Board approved the financial write-off of asset losses, with a total original value of inventory and fixed assets amounting to 1,789,961.56 yuan and an estimated loss of 978,888.18 yuan, impacting the total profit for 2024 by 825,135.58 yuan [3][4] - The financial write-off will not affect the company's profit and loss for the year 2025, as the impact has already been accounted for in previous years [3] Group 2 - The company announced the proposed cancellation of its subsidiary, Guangxi Wuzhou Zhongheng Pharmaceutical (Hong Kong) Co., Ltd., during the 29th meeting of the 10th Board of Directors held on June 13, 2025 [7][12] - The reason for the cancellation is that the subsidiary has not engaged in substantial operations since its establishment, and the company aims to optimize its organizational structure and improve operational efficiency [8] - The cancellation will not involve personnel arrangements and is not expected to have a significant impact on the company's financial and operational status [9] Group 3 - The Board of Directors approved the establishment of the "Overseas Investment Management Measures" and the "Financing Guarantee Management Measures," as well as the revision of the "Financing Management System" [13][15][16] - All resolutions passed with unanimous support from the board members, indicating strong consensus on these governance measures [14][15]